ArticleBioactive materials2026
An albumin-armed fibronectin fragment assembly on stents enables immune evasion, thrombosis prevention, and self-adaptive vascular cell selectivity.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reconstruction of a healthy endothelium following stent implantation is critical for enhancing vascular healing process. Surface engineering of stents with endothelial cell (EC)-selective molecules represents one of the most effective strategies to promote re-endothelialization. However, the adsorption of blood components accompanied by stenting inevitably mask the surface-modified bioactive molecules, leading to a reduction or alteration in the EC selectivity. Herein, we develop a serum albumin (SA)-armed, extracellular-matrix-derived, EC-selective peptide (i.e., REDV) (REDV-SA) self-assembling amyloid-like coating to address this issue. Our results show that the intrinsic biological properties of SA endow the REDV-SA-functionalized stents with immune escape capabilities and resistance to the adsorption of blood components, thereby creating a favorable microenvironment for REDV to exhibit its high EC selectivity. Of particular significance is the adaptive synergy between SA and REDV, which significantly reinforces EC selectivity by inhibiting smooth muscle cell (SMC) adhesion and preferentially promoting EC over SMC migration. Owing to its high EC selectivity, the stent functionalized with REDV-SA coating achieves nearly complete endothelial coverage within one week
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.